Tesofensine Capsules (500mcg) 100 Count

Tesofensine functions through potent triple monoamine reuptake inhibition, increasing synaptic concentrations of norepinephrine, serotonin, and dopamine.

1. Triple Monoamine Reuptake Inhibition:

Tesofensine is a potent non-selective inhibitor of all three monoamine transporters with in vitro binding affinities (IC₅₀ values): NET (norepinephrine transporter) 1.7-3.2 nM (highest affinity), SERT (serotonin transporter) 11 nM (intermediate affinity), DAT (dopamine transporter) 8.0-65 nM (lowest affinity among the three). This balanced triple reuptake inhibition increases synaptic concentrations of norepinephrine, serotonin, and dopamine in brain regions involved in appetite regulation, energy homeostasis, and reward processing. PET imaging studies in humans demonstrate dose-dependent dopamine transporter occupancy ranging from 18% to 77% at therapeutic doses, with maximum achievable DAT occupancy estimated at approximately 80%.

2. Appetite Suppression via α1 Adrenoceptor and D1 Receptor Pathways:

Preclinical studies (Axel et al., 2010) demonstrate that tesofensine induces appetite suppression through indirect stimulation of two primary receptor systems in the hypothalamus: α1 Adrenoceptor Pathway (Dominant Mechanism) — tesofensine blocks norepinephrine reuptake, increasing synaptic norepinephrine availability; accumulated norepinephrine indirectly stimulates α1 adrenoceptors, particularly in the paraventricular nucleus (PVN) of the hypothalamus; pharmacological blockade with the α1 antagonist prazosin almost completely abolishes tesofensine-induced food intake suppression; this pathway is primarily responsible for reducing meal frequency, meal size, and meal duration. Dopamine D1 Receptor Pathway (Secondary Mechanism) — tesofensine inhibits dopamine reuptake, allowing dopamine accumulation at synaptic sites; enhanced dopamine signaling activates D1 receptors in hypothalamic feeding centers; D1 receptor antagonism partially reduces, but does not eliminate, the appetite-suppressing effects; this pathway contributes to increased latency to first meal and reduced food-seeking behavior. Notably, α2 adrenoceptors, D2/D3 dopamine receptors, and 5-HT2A/C serotonin receptors do not significantly contribute to tesofensine's anorexigenic effects.

3. GABAergic Hypothalamic Neuron Silencing:

Recent research (Hjorth et al., 2024) reveals that tesofensine selectively inhibits a subset of lateral hypothalamus (LH) GABAergic neurons that promote feeding behavior. This inhibition occurs even during optogenetic stimulation, indicating potent suppression of neuronal activity. Diet-induced obese rats show greater weight loss with tesofensine than lean rats, correlating with differential modulation of LH neuronal ensembles and population activity. Chemogenetic silencing of LH GABAergic neurons combined with tesofensine administration produces additive effects on reducing food-seeking behavior (cumulative nose pokes), suggesting these neurons are critical targets for appetite control.

4. Energy Metabolism and Thermogenesis:

Clinical studies in humans (Hansen et al., 2010) demonstrate that tesofensine produces weight loss of 1.8 kg above placebo after just 2 weeks despite no dietary intervention. While total 24-hour energy expenditure shows no significant overall change, tesofensine increases nighttime energy expenditure by 4.6% (P<0.05) when adjusted for body composition. The drug also significantly increases 24-hour fat oxidation by 18 g (P<0.001) compared to placebo, indicating a metabolic shift toward lipid utilization. These effects suggest tesofensine may enhance resting energy expenditure and thermogenesis through sympathetic nervous system activation.

5. Striatal Dopamine Receptor Modulation:

Preclinical PET imaging studies (Van de Giessen et al., 2012) in diet-induced obese rats demonstrate that tesofensine decreases striatal dopamine D2/D3 receptor availability in the nucleus accumbens and dorsal striatum. This effect appears to be a direct pharmacological consequence of dopamine transporter blockade rather than the primary mechanism driving weight loss. The reduced receptor availability may reflect chronic dopamine elevation leading to compensatory receptor downregulation, potentially modulating food reward and hedonic feeding pathways.

Structural Features Supporting Activity:

• 8-Azabicyclo[3.2.1]octane core: Rigid bicyclic tropane scaffold providing structural constraint and influencing receptor binding
• Bis(4-chlorophenyl)methoxy substituent: Two para-chlorinated phenyl rings conferring high lipophilicity and monoamine transporter affinity
• Stereochemistry (1R,2R,3S,5S): Essential configuration for optimal transporter binding and pharmacological activity